Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype
Authors' conclusion
These proteomic findings will inform future biomarker and treatment development considering the unique tissue- and autoantibody-associated inflammation in JDM.
Study context
- Population
- Longitudinal North American cohort of patients with new-onset juvenile dermatomyositis (JDM) (Childhood Arthritis and Rheumatology Research Alliance Registry and 3 additional sites)24 JDM with 6-month samples
- Participants
- 56 vs 8
- Comparison
- Patients with new-onset JDM vs paediatric controls; JDM at onset vs 6-month follow-up; Myositis-specific autoantibody (MSA) subgroups
- JDMn = 56
- Paediatric controlsn = 8reference
- Outcome
- 3072 plasma proteins (Olink panel)
Methodological detailsexploratory proteomics, longitudinal cohort, multicentre
- Exploratory proteomics
- Longitudinal cohort
- Multicentre
Main finding
As reported in the abstract
- Persistent dysregulation of innate immune activation, cell death, and redox signalling at 6 months despite multidrug immunosuppression
- Overrepresentation of circulating endothelial proteins associated with disease activity; endothelial cell marker expression verified in JDM muscle and skin
- NXP2+ JDM-associated proteins reflected angiogenesis and extracellular matrix remodelling, expressed in endothelial cells and fibroblasts
- MDA5+ JDM associated with circulating type III interferon and surfactant proteins
Original publication
Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype. Ann Rheum Dis. Published 6 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →